Restructuring Activities

The Company has implemented a number of cost reduction or avoidance actions, including headcount reductions and facility closures and relocations primarily relating to the consolidation of certain of our facilities in China, the Buffalo BioMedical respiratory consolidation, and relocation of the corporate headquarters. The Buffalo Biomedical respiratory facility consolidation into Ball Ground, Georgia, was completed during the first quarter of 2017. The E&C Wuxi, China facility consolidation was completed during the second quarter of 2017, and the D&S China facility consolidation is expected to be completed by the end of 2017. Our corporate headquarters move from Garfield Heights, Ohio to Ball Ground, Georgia (which was official effective October 26, 2017) was substantially completed during the third quarter of 2017, and the Company’s Garfield Heights headquarters lease commitment ends December 31, 2017.

The following table is a summary of the severance and other restructuring costs, which included employee-related costs, facility rent and exit costs, relocation, recruiting, travel and other, for the three months and nine months ended September 30, 2017 and 2016:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Severance:
Cost of sales	$	52	$	159	$	731	$	3,501
Selling, general, and administrative expenses	920		43		2,767		2,382
Total severance costs	$	972	$	202	$	3,498	$	5,883
Other restructuring:
Cost of sales	$	278	$	—	$	4,072	$	—
Selling, general, and administrative expenses	1,499		103		4,847		420
Total other restructuring costs	$	1,777	$	103	$	8,919	$	420

Total restructuring costs	$	2,749	$	305	$	12,417	$	6,303

The Company is closely monitoring its end markets and order rates and will continue to take appropriate and timely actions as necessary. The Company currently expects additional restructuring costs in the remaining three months of 2017 to be approximately $1,530 ($1,000 - D&S, $310 - BioMedical, and $220 - Corporate), but further actions may be required based on future business conditions.

The following tables summarize the Company’s restructuring activities for the three and nine months ended September 30, 2017 and 2016:



	Three Months Ended September 30, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of June 30, 2017	$	—		$	1,865		$	847		$	1,493		$	4,205
Restructuring costs	162			648			516			1,423			2,749
Cash payments	(157		)	(1,381		)	(803		)	(1,480		)	(3,821		)
Acquired restructuring reserve	194			—			—			—			194
Balance as of September 30, 2017	$	199		$	1,132		$	560		$	1,436		$	3,327



	Three Months Ended September 30, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of June 30, 2016	$	544		$	4,796		$	368		$	276		$	5,984
Restructuring costs	159			118			—			28			305
Cash payments	(267		)	(1,160		)	(168		)	(219		)	(1,814		)
Balance as of September 30, 2016	$	436		$	3,754		$	200		$	85		$	4,475



	Nine Months Ended September 30, 2017
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2016	$	127		$	2,864		$	1,308		$	3,025		$	7,324
Restructuring costs	2,245			1,085			4,527			4,560			12,417
Cash payments	(2,367		)	(2,817		)	(5,275		)	(6,149		)	(16,608		)
Acquired restructuring reserve	194			—			—			—			194
Balance as of September 30, 2017	$	199		$	1,132		$	560		$	1,436		$	3,327



	Nine Months Ended September 30, 2016
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate			Total
Balance as of December 31, 2015	$	1,106		$	3,446		$	430		$	850		$	5,832
Restructuring costs	821			3,929			521			1,032			6,303
Cash payments	(1,491		)	(3,621		)	(751		)	(1,797		)	(7,660		)
Balance as of September 30, 2016	$	436		$	3,754		$	200		$	85		$	4,475